Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Dabcyl-LNKRELHETQE-Edans + H2O
?
Dabcyl-LNKRKLHETQE-Edans + H2O
?
Dabcyl-LNKRLLEETQE-Edans + H2O
?
DABCYL-LNKRLLHETQ-EDANS + H2O
?
-
fluorogenic peptide corresponding to the PEXEL motif for histidine-rich protein II is cleaved by PM V. Mutation of P1 Leu or P3 Arg abolishes cleavage
-
-
?
Dabcyl-LNKRLLSETQE-Edans + H2O
?
Dabcyl-LNKRLLVETQE-Edans + H2O
?
about 150% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-RNKKTLAQKQ-E-Edans + H2O
?
Dabcyl-RNKRTIAQKQ-E-Edans + H2O
?
Dabcyl-RNKRTLAQKQ-E-Edans + H2O
?
Dabcyl-RYVRELSETE-Edans + H2O
?
about 68% activity compared to the EMP2 peptide Dabcyl-RYVRILSETE-Edans
-
-
?
Dabcyl-RYVRELSETEE-Edans + H2O
?
about 10-25% activity compared to the EMP2 peptide Dabcyl-RYVRILSETEE-Edans
-
-
?
Dabcyl-RYVRILEETE-Edans + H2O
?
about 28% activity compared to the EMP2 peptide Dabcyl-RYVRILSETE-Edans
-
-
?
Dabcyl-RYVRILEETEE-Edans + H2O
?
about 7-30% activity compared to the EMP2 peptide Dabcyl-RYVRILSETEE-Edans
-
-
?
DABCYL-RYVRILSETE-EDANS + H2O
?
-
fluorogenic peptide corresponding to the PEXEL motif for PfEMP2 is cleaved by PM V. Mutation of P1 Leu or P3 Arg abolishes cleavage
-
-
?
Dabcyl-RYVRILVETE-Edans + H2O
?
about 28% activity compared to the EMP2 peptide Dabcyl-RYVRILSETE-Edans
-
-
?
Dabcyl-RYVRILVETEE-Edans + H2O
?
about 8-30% activity compared to the EMP2 peptide Dabcyl-RYVRILSETEE-Edans
-
-
?
Dabcyl-RYVRKLSETE-Edans + H2O
?
about 70% activity compared to the EMP2 peptide Dabcyl-RYVRILSETE-Edans
-
-
?
Dabcyl-RYVRKLSETEE-Edans + H2O
?
about 70% activity compared to the EMP2 peptide Dabcyl-RYVRILSETEE-Edans
-
-
?
EMP2 + H2O
Dabcyl-RYVRIL + SETE-Edans
i.e. Dabcyl-RYVRILSETE-Edans
-
-
?
erythrocyte membrane protein 2 + H2O
?
i.e. Dabcyl-RYVRILSETEE-Edans
-
-
?
Hemoglobin + H2O
?
-
-
-
?
histidine-rich protein II + H2O
?
i.e. Dabcyl-LNKRLLHETQE-Edans
-
-
?
HRP2 peptide + H2O
?
-
-
-
?
KAHRP protein + H2O
?
-
-
-
?
MSP1 peptide + H2O
?
-
-
-
?
additional information
?
-
Dabcyl-LNKRELHETQE-Edans + H2O
?
about 50% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-LNKRELHETQE-Edans + H2O
?
about 50% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-LNKRKLHETQE-Edans + H2O
?
about 130% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-LNKRKLHETQE-Edans + H2O
?
about 130% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-LNKRLLEETQE-Edans + H2O
?
about 50% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-LNKRLLEETQE-Edans + H2O
?
about 50% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-LNKRLLSETQE-Edans + H2O
?
about 180% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-LNKRLLSETQE-Edans + H2O
?
about 180% activity compared to the HRPII peptide Dabcyl-LNKRLLHETQE-Edans
-
-
?
Dabcyl-RNKKTLAQKQ-E-Edans + H2O
?
-
-
-
?
Dabcyl-RNKKTLAQKQ-E-Edans + H2O
?
-
-
-
?
Dabcyl-RNKRTIAQKQ-E-Edans + H2O
?
-
-
-
?
Dabcyl-RNKRTIAQKQ-E-Edans + H2O
?
-
-
-
?
Dabcyl-RNKRTLAQKQ-E-Edans + H2O
?
-
-
-
?
Dabcyl-RNKRTLAQKQ-E-Edans + H2O
?
-
-
-
?
EMP2 + H2O
?
i.e. Dabcyl-RYVRILSETEE-Edans
-
-
?
EMP2 + H2O
?
i.e. Dabcyl-RYVRILSETE-Edans, most efficient substrate. Replacing Ser by Val or Glu of the PfEMP2 peptide P1' position markedly reduces the enzyme activity of the enzyme
-
-
?
HRPII + H2O
?
i.e. Dabcyl-LNKRLLHETQE-Edans
-
-
?
HRPII + H2O
?
-
i.e. Dabcyl-LNKRLLHETQE-Edans
-
-
?
HRPII + H2O
?
i.e. Dabcyl-LNKRLLHETQE-Edans. Replacing His by Val or Ser of the HRPII peptide P1' position increases the cleavage activity
-
-
?
additional information
?
-
-
PM V pull-downs identified an ER-resident HSP70 and HSP101 as associated proteins
-
-
?
additional information
?
-
-
plasmepsin V recognizes pentameric motif RxLxE/Q/D of exported proteins. Plasmepsin V cleavage reveals the export signal xE/Q/D at the N-terminus of cargo proteins. Plasmepsin V activity is essential and linked with other key export events
-
-
?
additional information
?
-
no activity with DABCYL-KAVHYLEHNVKE-EDANS and Dabcyl-RYVAIASATEE-Edans
-
-
?
additional information
?
-
-
no activity with DABCYL-KAVHYLEHNVKE-EDANS and Dabcyl-RYVAIASATEE-Edans
-
-
?
additional information
?
-
no activity with DABCYL-KAVHYLEHNVKE-EDANS and Dabcyl-RYVAIASATEE-Edans
-
-
?
additional information
?
-
-
no activity with DABCYL-KAVHYLEHNVKE-EDANS and Dabcyl-RYVAIASATEE-Edans
-
-
?
additional information
?
-
no activity with DABCYL-KAVHYLEHNVKE-EDANS and Dabcyl-RYVAIASATEE-Edans
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-2,2-dimethylpropyl heptanoate
58.6% residual activity at 0.05 mM
3-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-2,2-dimethylpropyl tridecanoate
49.5% residual activity at 0.05 mM
3-amino-N-[(benzyloxy)carbonyl]-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
4-amino-N-[(benzyloxy)carbonyl]-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
Ca2+
about 75% residual activity at 0.5 mM
menisporopsin A
10-30% inhibition at 0.01 mM, 40-60% inhibition at 0.1 mM
N'-benzyl-2-(8-methyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-3-yl)-N'-phenylacetohydrazide
ZINC36767691
N,N'-(propane-1,3-diyl)bis(2-bromobenzamide)
ZINC02802008
N-(2-[[(2-fluorophenyl)methyl]amino]-2-oxoethyl)-2-iodobenzamide
ZINC07922110
N-[(benzyloxy)carbonyl]-3-carbamimidamido-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N-[(benzyloxy)carbonyl]-4-carbamimidamido-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N-[(benzyloxy)carbonyl]-O-carbamimidamido-L-homoseryl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-L-arginyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N-carbamimidoyl-L-glutaminyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(methylsulfonyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-cyanocarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-hydroxycarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-methoxycarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-methylcarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(N-nitrocarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-(propan-2-yl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-carbamimidoyl-N5-methyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-carbamoyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N2-[(benzyloxy)carbonyl]-N5-ethanimidoyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
N5-acetyl-N2-[(benzyloxy)carbonyl]-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
-
NKPSL4
59.3% residual activity at 0.05 mM
phenylmethylsulfonyl fluoride
rhinacanthin-M
60.9% residual activity at 0.05 mM
rhinacanthin-N
63.3% residual activity at 0.05 mM
tert-butyl (3-[[(2-methyl-1H-indol-3-yl)carbonyl]amino]propyl)(pyridin-3-ylmethyl)carbamate
ZINC72012008
Hg2+
-
Hg2+
about 20-30% residual activity at 0.5 mM
lopinavir
-
-
nelfinavir
-
-
nelfinavir
the truncated enzyme PMVm84 exhibits about 53% residual activity at 0.1 mM
pepstatin A
-
-
phenylmethylsulfonyl fluoride
the truncated enzyme PMVm84 exhibits about 70% residual activity at 0.1 mM
phenylmethylsulfonyl fluoride
about 20% inhibition at 0.01 mM, 50-70% inhibition at 0.1 mM
ritonavir
-
-
saquinavir
-
-
WEHI-842
potent inhibitor
WEHI-842
potent inhibitor
WEHI-842
potent inhibitor
WEHI-916
potent inhibitor
additional information
-
in contrast to the food vacuole plasmepsins, detergent-solubilized PM V does not bind the aspartic protease inhibitor pepstatin
-
additional information
not influenced by Ca2+; pepstatin A cannot inhibit refolded enzyme activity
-
additional information
-
not influenced by Ca2+; pepstatin A cannot inhibit refolded enzyme activity
-
additional information
the truncated enzyme PMVm84 is not inhibited by pepstatin A
-
additional information
-
the truncated enzyme PMVm84 is not inhibited by pepstatin A
-
additional information
not inhibited by pepstatin A and nelfinavir
-
additional information
-
not inhibited by pepstatin A and nelfinavir
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Malaria
Correction: Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Malaria
Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P2 position of PEXEL peptidomimetics.
Malaria
Flap flexibility amongst plasmepsins I, II, III, IV, and V: Sequence, structural, and molecular dynamics analyses.
Malaria
In silico validation of novel inhibitors of malarial aspartyl protease, plasmepsin V and antimalarial efficacy prediction.
Malaria
Inhibition of Plasmepsin V activity demonstrates its essential role in protein export, PfEMP1 display, and survival of malaria parasites.
Malaria
New insights into protein export in malaria parasites.
Malaria
Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Malaria
Plasmepsin V cleaves malaria effector proteins in a distinct endoplasmic reticulum translocation interactome for export to the erythrocyte.
Malaria
Plasmepsin V, a secret weapon against malaria.
Malaria
Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.
Malaria
Targeting Plasmodium Plasmepsin V: Hitting Two Birds with One Stone.
Malaria
The C-terminal portion of the cleaved HT motif is necessary and sufficient to mediate export of proteins from the malaria parasite into its host cell.
Malaria
The zymogen of plasmepsin V from Plasmodium falciparum is enzymatically active.
Malaria
Yield improvement and enzymatic dissection of Plasmodium falciparum plasmepsin V.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00693 - 0.02443
Dabcyl-RNKRTLAQKQ-E-Edans
0.00693
Dabcyl-RNKRTLAQKQ-E-Edans
at pH 6.4 and 37°C
0.02443
Dabcyl-RNKRTLAQKQ-E-Edans
at pH 6.4 and 37°C
0.00021
EMP2
truncated enzyme PMVp37, at pH 6.5 and 37°C
-
0.00029
EMP2
truncated enzyme PMVm84, at pH 6.5 and 37°C
-
0.00066
EMP2
proenzyme, at pH 6.5 and 25°C
-
0.00139
EMP2
mature enzyme, at pH 6.5 and 25°C
-
0.00342
EMP2
mutant enzyme C178S, at pH 6.5 and 25°C
-
0.00384
EMP2
wild type enzyme, at pH 6.5 and 25°C
-
0.00478
EMP2
mutant enzyme C178A, at pH 6.5 and 25°C
-
0.00969
EMP2
mutant enzyme D118N, at pH 6.5 and 25°C
-
0.0135
EMP2
mutant enzyme D365N, at pH 6.5 and 25°C
-
0.00038
HRPII
truncated enzyme PMVm84, at pH 6.5 and 37°C
-
0.00093
HRPII
proenzyme, at pH 6.5 and 25°C
-
0.00096
HRPII
mature enzyme, at pH 6.5 and 25°C
-
0.00114
HRPII
truncated enzyme PMVp37, at pH 6.5 and 37°C
-
0.00374
HRPII
mutant enzyme C178S, at pH 6.5 and 25°C
-
0.00422
HRPII
wild type enzyme, at pH 6.5 and 25°C
-
0.00509
HRPII
mutant enzyme C178A, at pH 6.5 and 25°C
-
0.00957
HRPII
mutant enzyme D118N, at pH 6.5 and 25°C
-
0.0142
HRPII
mutant enzyme D365N, at pH 6.5 and 25°C
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.86 - 3.64
Dabcyl-RNKRTLAQKQ-E-Edans
1.86
Dabcyl-RNKRTLAQKQ-E-Edans
at pH 6.4 and 37°C
3.64
Dabcyl-RNKRTLAQKQ-E-Edans
at pH 6.4 and 37°C
0.121
EMP2
proenzyme, at pH 6.5 and 25°C
-
0.19
EMP2
truncated enzyme PMVm84, at pH 6.5 and 37°C
-
0.203
EMP2
mature enzyme, at pH 6.5 and 25°C
-
0.23
EMP2
truncated enzyme PMVp37, at pH 6.5 and 37°C
-
2.26
EMP2
mutant enzyme D365N, at pH 6.5 and 25°C
-
2.56
EMP2
mutant enzyme D118N, at pH 6.5 and 25°C
-
3.01
EMP2
mutant enzyme C178A, at pH 6.5 and 25°C
-
3.12
EMP2
wild type enzyme, at pH 6.5 and 25°C
-
3.35
EMP2
mutant enzyme C178S, at pH 6.5 and 25°C
-
0.05
HRPII
mature enzyme, at pH 6.5 and 25°C
-
0.06
HRPII
proenzyme, at pH 6.5 and 25°C
-
0.12
HRPII
truncated enzyme PMVm84, at pH 6.5 and 37°C
-
0.13
HRPII
truncated enzyme PMVp37, at pH 6.5 and 37°C
-
2.19
HRPII
mutant enzyme D365N, at pH 6.5 and 25°C
-
2.35
HRPII
mutant enzyme D118N, at pH 6.5 and 25°C
-
2.79
HRPII
mutant enzyme C178A, at pH 6.5 and 25°C
-
2.97
HRPII
wild type enzyme, at pH 6.5 and 25°C
-
3.36
HRPII
mutant enzyme C178S, at pH 6.5 and 25°C
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
80 - 530
Dabcyl-RNKRTLAQKQ-E-Edans
80
Dabcyl-RNKRTLAQKQ-E-Edans
at pH 6.4 and 37°C
530
Dabcyl-RNKRTLAQKQ-E-Edans
at pH 6.4 and 37°C
146
EMP2
mature enzyme, at pH 6.5 and 25°C
-
167
EMP2
mutant enzyme D365N, at pH 6.5 and 25°C
-
183
EMP2
proenzyme, at pH 6.5 and 25°C
-
264
EMP2
mutant enzyme D118N, at pH 6.5 and 25°C
-
630
EMP2
mutant enzyme C178A, at pH 6.5 and 25°C
-
813
EMP2
wild type enzyme, at pH 6.5 and 25°C
-
981
EMP2
mutant enzyme C178S, at pH 6.5 and 25°C
-
6500
EMP2
truncated enzyme PMVm84, at pH 6.5 and 37°C
-
10900
EMP2
truncated enzyme PMVp37, at pH 6.5 and 37°C
-
55
HRPII
mature enzyme, at pH 6.5 and 25°C
-
66
HRPII
proenzyme, at pH 6.5 and 25°C
-
110
HRPII
truncated enzyme PMVp37, at pH 6.5 and 37°C
-
154
HRPII
mutant enzyme D365N, at pH 6.5 and 25°C
-
245
HRPII
mutant enzyme D118N, at pH 6.5 and 25°C
-
310
HRPII
truncated enzyme PMVm84, at pH 6.5 and 37°C
-
549
HRPII
mutant enzyme C178A, at pH 6.5 and 25°C
-
704
HRPII
wild type enzyme, at pH 6.5 and 25°C
-
898
HRPII
mutant enzyme C178S, at pH 6.5 and 25°C
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.02225
3-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-2,2-dimethylpropyl heptanoate
Plasmodium falciparum
at pH 6.5 and 25°C
0.06894
3-(3-hydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-2,2-dimethylpropyl tridecanoate
Plasmodium falciparum
at pH 6.5 and 25°C
0.05
3-amino-N-[(benzyloxy)carbonyl]-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.05
4-amino-N-[(benzyloxy)carbonyl]-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.0856
N'-benzyl-2-(8-methyl-2,4-dioxo-1,3-diazaspiro[4.5]dec-3-yl)-N'-phenylacetohydrazide
Plasmodium falciparum
pH and temperature not specified in the publication
0.05
N-[(benzyloxy)carbonyl]-3-carbamimidamido-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.05
N-[(benzyloxy)carbonyl]-4-carbamimidamido-L-phenylalanyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.00274
N-[(benzyloxy)carbonyl]-O-carbamimidamido-L-homoseryl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.000128
N2-[(benzyloxy)carbonyl]-L-arginyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.0416
N2-[(benzyloxy)carbonyl]-N-carbamimidoyl-L-glutaminyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.05
N2-[(benzyloxy)carbonyl]-N5-(methylsulfonyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.05
N2-[(benzyloxy)carbonyl]-N5-(N-cyanocarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.00388
N2-[(benzyloxy)carbonyl]-N5-(N-hydroxycarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.18
N2-[(benzyloxy)carbonyl]-N5-(N-methoxycarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.0377
N2-[(benzyloxy)carbonyl]-N5-(N-methylcarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.05
N2-[(benzyloxy)carbonyl]-N5-(N-nitrocarbamimidoyl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.05
N2-[(benzyloxy)carbonyl]-N5-(propan-2-yl)-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.05
N2-[(benzyloxy)carbonyl]-N5-carbamimidoyl-N5-methyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.05
N2-[(benzyloxy)carbonyl]-N5-carbamoyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.0403
N2-[(benzyloxy)carbonyl]-N5-ethanimidoyl-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
at pH 6.4 and 37°C
0.05
N5-acetyl-N2-[(benzyloxy)carbonyl]-L-ornithyl-N-[(3S,4S)-3-hydroxy-6-methyl-1-oxo-1-[(2-phenylethyl)amino]heptan-4-yl]-L-valinamide
Plasmodium falciparum
IC50 above 0.05 mM, at pH 6.4 and 37°C
0.0487
tert-butyl (3-[[(2-methyl-1H-indol-3-yl)carbonyl]amino]propyl)(pyridin-3-ylmethyl)carbamate
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000002 - 0.00001
WEHI-842
0.0000021 - 0.000121
WEHI-916
0.0000002
WEHI-842
Plasmodium falciparum
at pH 6.4 and 37°C
0.0000004
WEHI-842
Plasmodium vivax
at pH 6.4 and 37°C
0.00001
WEHI-842
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000021
WEHI-916
Plasmodium vivax
at pH 6.4 and 37°C
0.0000035
WEHI-916
Plasmodium falciparum
at pH 6.4 and 37°C
0.000121
WEHI-916
Plasmodium falciparum
pH and temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Klemba, M.; Goldberg, D.E.
Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum.
Mol. Biochem. Parasitol.
143
183-191
2005
Plasmodium falciparum
brenda
Russo, I.; Babbitt, S.; Muralidharan, V.; Butler, T.; Oksman, A.; Goldberg, D.E.
Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte
Nature
463
632-636
2010
Plasmodium falciparum
brenda
Boddey, J.A.; Hodder, A.N.; Guenther, S.; Gilson, P.R.; Patsiouras, H.; Kapp, E.A.; Pearce, J.A.; de Koning-Ward, T.F.; Simpson, R.J.; Crabb, B.S.; Cowman, A.F.
An aspartyl protease directs malaria effector proteins to the host cell
Nature
463
627-631
2010
Plasmodium falciparum
brenda
Sittikul, P.; Songtawee, N.; Kongkathip, N.; Boonyalai, N.
In vitro and in silico studies of naphthoquinones and peptidomimetics toward Plasmodium falciparum plasmepsin V
Biochimie
152
159-173
2018
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
Gazdik, M.; Jarman, K.E.; ONeill, M.T.; Hodder, A.N.; Lowes, K.N.; Jousset Sabroux, H.; Cowman, A.F.; Boddey, J.A.; Sleebs, B.E.
Exploration of the P3 region of PEXEL peptidomimetics leads to a potent inhibitor of the Plasmodium protease, plasmepsin V
Bioorg. Med. Chem.
24
1993-2010
2016
Plasmodium falciparum (Q8I6Z5)
brenda
Meissner, K.A.; Kronenberger, T.; Maltarollo, V.G.; Trossini, G.H.G.; Wrenger, C.
Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening
Chem. Biol. Drug Des.
93
300-312
2019
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
Boonyalai, N.; Sittikul, P.; Yuvaniyama, J.
Plasmodium falciparum plasmepsin V (PfPMV) Insights into recombinant expression, substrate specificity and active site structure
Mol. Biochem. Parasitol.
201
5-15
2015
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
Sappakhaw, K.; Takasila, R.; Sittikul, P.; Wattana-Amorn, P.; Assavalapsakul, W.; Boonyalai, N.
Biochemical characterization of plasmepsin V from Plasmodium vivax Thailand isolates Substrate specificity and enzyme inhibition
Mol. Biochem. Parasitol.
204
51-63
2015
Plasmodium vivax (A0A0H4FQ60), Plasmodium vivax, Plasmodium vivax Thai (A0A0H4FQ60)
brenda
Loymunkong, C.; Sittikul, P.; Songtawee, N.; Wongpanya, R.; Boonyalai, N.
Yield improvement and enzymatic dissection of Plasmodium falciparum plasmepsin V
Mol. Biochem. Parasitol.
231
111188
2019
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
L, M.; Soliman, M.E.
The binding landscape of plasmepsin V and the implications for flap dynamics
Mol. Biosyst.
12
1457-1467
2016
Plasmodium vivax
brenda
Marapana, D.S.; Dagley, L.F.; Sandow, J.J.; Nebl, T.; Triglia, T.; Pasternak, M.; Dickerman, B.K.; Crabb, B.S.; Gilson, P.R.; Webb, A.I.; Boddey, J.A.; Cowman, A.F.
Plasmepsin V cleaves malaria effector proteins in a distinct endoplasmic reticulum translocation interactome for export to the erythrocyte
Nat. Microbiol.
3
1010-1022
2018
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
Hodder, A.N.; Sleebs, B.E.; Czabotar, P.E.; Gazdik, M.; Xu, Y.; ONeill, M.T.; Lopaticki, S.; Nebl, T.; Triglia, T.; Smith, B.J.; Lowes, K.; Boddey, J.A.; Cowman, A.F.
Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes
Nat. Struct. Mol. Biol.
22
590-596
2015
Plasmodium vivax (Q6PRR9), Plasmodium vivax, Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
Tarr, S.J.; Osborne, A.R.
Experimental determination of the membrane topology of the Plasmodium protease plasmepsin V
PLoS ONE
10
e0121786
2015
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
Boonyalai, N.; Collins, C.R.; Hackett, F.; Withers-Martinez, C.; Blackman, M.J.
Essentiality of Plasmodium falciparum plasmepsin V
PLoS ONE
13
e0207621
2018
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
McGillewie, L.; Soliman, M.E.
Flap flexibility amongst plasmepsins I, II, III, IV, and V Sequence, structural, and molecular dynamics analyses
Proteins
83
1693-1705
2015
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda
Bedi, R.K.; Patel, C.; Mishra, V.; Xiao, H.; Yada, R.Y.; Bhaumik, P.
Understanding the structural basis of substrate recognition by Plasmodium falciparum plasmepsin V to aid in the design of potent inhibitors
Sci. Rep.
6
31420
2016
Plasmodium falciparum (Q8I6Z5), Plasmodium falciparum
brenda